Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines

Weiguang Wang, H. L. McLeod, J. Cassidy

    Research output: Contribution to journalArticle

    150 Citations (Scopus)

    Abstract

    5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours. Resistance of cancer cells to 5-FU is considered the major obstacle for successful chemotherapy. NF-kappaB is a transcription factor. Cancer cells with high NF-kappaB nuclear activity demonstrate robust chemo- and radio-resistance. We demonstrated that nuclear NF-kappaB activity in CRC cell lines, DLD-1 and RKOWT, was significantly induced by 5-FU in a concentration- and time-dependent manner. 5-FU induced IkappaBalpha degradation and promoted both NF-kappaB nuclear translocation and its DNA binding activity. 5-FU treatment did not influence the activities of AP-1, AP-2, Oct-1, SP-1, CRE-B and TFIID. Disulfiram (DS), a clinically used anti-alcoholism drug, strongly inhibited constitutive and 5-FU-induced NF-kappaB activity in a dose-dependent manner. DS inhibited both NF-kappaB nuclear translocation and DNA binding activity but had no effect on 5-FU-induced IkappaBalpha degradation. Used in combination, DS significantly enhanced the apoptotic effect of 5-FU on DLD-1 and RKOWT cell lines and synergistically potentiated the cytotoxicity of 5-FU to both cell lines. DS also effectively abolished 5-FU chemoresistance in a 5-FU resistant cell line H630(5-FU) in vitro. As DS has extensive preclinical and clinical experience, translating its anticancer usage from in vitro study to clinical trials is relatively straightforward. (C) 2003 Wiley-Liss, Inc.

    Original languageEnglish
    Pages (from-to)504-511
    Number of pages7
    JournalInternational Journal of Cancer
    Volume104
    Issue number4
    DOIs
    Publication statusPublished - 2003

    Keywords

    • NF-kappa B
    • I kappa B alpha
    • 5-FU
    • disulfiram
    • colorectal cancer
    • INDUCED APOPTOSIS
    • INDUCIBLE CHEMORESISTANCE
    • TRANSCRIPTION FACTORS
    • BONE-MARROW
    • IN-VITRO
    • ACTIVATION
    • ALPHA
    • DIETHYLDITHIOCARBAMATE
    • INDUCTION
    • TOXICITY

    Cite this

    Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. / Wang, Weiguang; McLeod, H. L.; Cassidy, J.

    In: International Journal of Cancer, Vol. 104, No. 4, 2003, p. 504-511.

    Research output: Contribution to journalArticle

    @article{2832c61282154ffca53588371da74b40,
    title = "Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines",
    abstract = "5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours. Resistance of cancer cells to 5-FU is considered the major obstacle for successful chemotherapy. NF-kappaB is a transcription factor. Cancer cells with high NF-kappaB nuclear activity demonstrate robust chemo- and radio-resistance. We demonstrated that nuclear NF-kappaB activity in CRC cell lines, DLD-1 and RKOWT, was significantly induced by 5-FU in a concentration- and time-dependent manner. 5-FU induced IkappaBalpha degradation and promoted both NF-kappaB nuclear translocation and its DNA binding activity. 5-FU treatment did not influence the activities of AP-1, AP-2, Oct-1, SP-1, CRE-B and TFIID. Disulfiram (DS), a clinically used anti-alcoholism drug, strongly inhibited constitutive and 5-FU-induced NF-kappaB activity in a dose-dependent manner. DS inhibited both NF-kappaB nuclear translocation and DNA binding activity but had no effect on 5-FU-induced IkappaBalpha degradation. Used in combination, DS significantly enhanced the apoptotic effect of 5-FU on DLD-1 and RKOWT cell lines and synergistically potentiated the cytotoxicity of 5-FU to both cell lines. DS also effectively abolished 5-FU chemoresistance in a 5-FU resistant cell line H630(5-FU) in vitro. As DS has extensive preclinical and clinical experience, translating its anticancer usage from in vitro study to clinical trials is relatively straightforward. (C) 2003 Wiley-Liss, Inc.",
    keywords = "NF-kappa B, I kappa B alpha, 5-FU, disulfiram, colorectal cancer, INDUCED APOPTOSIS, INDUCIBLE CHEMORESISTANCE, TRANSCRIPTION FACTORS, BONE-MARROW, IN-VITRO, ACTIVATION, ALPHA, DIETHYLDITHIOCARBAMATE, INDUCTION, TOXICITY",
    author = "Weiguang Wang and McLeod, {H. L.} and J. Cassidy",
    year = "2003",
    doi = "10.1002/ijc.10972",
    language = "English",
    volume = "104",
    pages = "504--511",
    journal = "International Journal of Cancer",
    issn = "0020-7136",
    publisher = "Wiley-Liss Inc.",
    number = "4",

    }

    TY - JOUR

    T1 - Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines

    AU - Wang, Weiguang

    AU - McLeod, H. L.

    AU - Cassidy, J.

    PY - 2003

    Y1 - 2003

    N2 - 5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours. Resistance of cancer cells to 5-FU is considered the major obstacle for successful chemotherapy. NF-kappaB is a transcription factor. Cancer cells with high NF-kappaB nuclear activity demonstrate robust chemo- and radio-resistance. We demonstrated that nuclear NF-kappaB activity in CRC cell lines, DLD-1 and RKOWT, was significantly induced by 5-FU in a concentration- and time-dependent manner. 5-FU induced IkappaBalpha degradation and promoted both NF-kappaB nuclear translocation and its DNA binding activity. 5-FU treatment did not influence the activities of AP-1, AP-2, Oct-1, SP-1, CRE-B and TFIID. Disulfiram (DS), a clinically used anti-alcoholism drug, strongly inhibited constitutive and 5-FU-induced NF-kappaB activity in a dose-dependent manner. DS inhibited both NF-kappaB nuclear translocation and DNA binding activity but had no effect on 5-FU-induced IkappaBalpha degradation. Used in combination, DS significantly enhanced the apoptotic effect of 5-FU on DLD-1 and RKOWT cell lines and synergistically potentiated the cytotoxicity of 5-FU to both cell lines. DS also effectively abolished 5-FU chemoresistance in a 5-FU resistant cell line H630(5-FU) in vitro. As DS has extensive preclinical and clinical experience, translating its anticancer usage from in vitro study to clinical trials is relatively straightforward. (C) 2003 Wiley-Liss, Inc.

    AB - 5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours. Resistance of cancer cells to 5-FU is considered the major obstacle for successful chemotherapy. NF-kappaB is a transcription factor. Cancer cells with high NF-kappaB nuclear activity demonstrate robust chemo- and radio-resistance. We demonstrated that nuclear NF-kappaB activity in CRC cell lines, DLD-1 and RKOWT, was significantly induced by 5-FU in a concentration- and time-dependent manner. 5-FU induced IkappaBalpha degradation and promoted both NF-kappaB nuclear translocation and its DNA binding activity. 5-FU treatment did not influence the activities of AP-1, AP-2, Oct-1, SP-1, CRE-B and TFIID. Disulfiram (DS), a clinically used anti-alcoholism drug, strongly inhibited constitutive and 5-FU-induced NF-kappaB activity in a dose-dependent manner. DS inhibited both NF-kappaB nuclear translocation and DNA binding activity but had no effect on 5-FU-induced IkappaBalpha degradation. Used in combination, DS significantly enhanced the apoptotic effect of 5-FU on DLD-1 and RKOWT cell lines and synergistically potentiated the cytotoxicity of 5-FU to both cell lines. DS also effectively abolished 5-FU chemoresistance in a 5-FU resistant cell line H630(5-FU) in vitro. As DS has extensive preclinical and clinical experience, translating its anticancer usage from in vitro study to clinical trials is relatively straightforward. (C) 2003 Wiley-Liss, Inc.

    KW - NF-kappa B

    KW - I kappa B alpha

    KW - 5-FU

    KW - disulfiram

    KW - colorectal cancer

    KW - INDUCED APOPTOSIS

    KW - INDUCIBLE CHEMORESISTANCE

    KW - TRANSCRIPTION FACTORS

    KW - BONE-MARROW

    KW - IN-VITRO

    KW - ACTIVATION

    KW - ALPHA

    KW - DIETHYLDITHIOCARBAMATE

    KW - INDUCTION

    KW - TOXICITY

    U2 - 10.1002/ijc.10972

    DO - 10.1002/ijc.10972

    M3 - Article

    VL - 104

    SP - 504

    EP - 511

    JO - International Journal of Cancer

    JF - International Journal of Cancer

    SN - 0020-7136

    IS - 4

    ER -